|
Back to Home » November 2021 News » Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules |
Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules |
November 08, 2021
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it has closed its previously...
Source URL: https://www.prnewswire.com:443/news-releases/oramed-announces-closing-of-50-million-registered-direct-offering-of-common-stock-priced-at-the-market-under-nasdaq-rules-301418476.html
|
|
|
|
